淋巴因子激活的杀伤细胞现象。III. 白细胞介素-2足以将外周血淋巴细胞直接激活为淋巴因子激活的杀伤细胞的证据。
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
作者信息
Grimm E A, Robb R J, Roth J A, Neckers L M, Lachman L B, Wilson D J, Rosenberg S A
出版信息
J Exp Med. 1983 Oct 1;158(4):1356-61. doi: 10.1084/jem.158.4.1356.
Abstract
Purified interleukin 2 (IL-2) was found to be sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer (LAK) cells. The LAK activation factor was directly and consistently associated with IL-2 activity using classic protein purification techniques, adsorption to IL-2-dependent cell lines, and inhibition with anti-Tac antibody. As yet, no other cytokines have been found that perform the same role.
摘要
纯化的白细胞介素2（IL-2）被发现足以将外周血淋巴细胞直接激活为淋巴因子激活的杀伤细胞（LAK细胞）。使用经典的蛋白质纯化技术、吸附到依赖IL-2的细胞系以及用抗Tac抗体抑制，LAK激活因子与IL-2活性直接且始终相关。迄今为止，尚未发现其他细胞因子具有相同的作用。
相似文献
1
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.淋巴因子激活的杀伤细胞现象。III. 白细胞介素-2足以将外周血淋巴细胞直接激活为淋巴因子激活的杀伤细胞的证据。
J Exp Med. 1983 Oct 1;158(4):1356-61. doi: 10.1084/jem.158.4.1356.
2
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.体内白细胞介素-2治疗诱导的淋巴因子激活的杀伤活性：CD2和leu19抗原表达增加但CD16抗原表达阴性的淋巴细胞起主要作用。
Cancer Res. 1989 Jul 1;49(13):3680-8.
3
4
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.淋巴因子激活的杀伤细胞现象。II. 前体细胞表型在血清学上与外周T淋巴细胞、记忆性细胞毒性胸腺来源淋巴细胞及自然杀伤细胞不同。
J Exp Med. 1983 Mar 1;157(3):884-97. doi: 10.1084/jem.157.3.884.
5
6
7
Functional studies on the precursors of human lymphokine-activated killer cells.人淋巴因子激活杀伤细胞前体的功能研究。
Cell Immunol. 1985 Dec;96(2):338-50. doi: 10.1016/0008-8749(85)90365-x.
8
IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.白细胞介素-4调节白细胞介素-2诱导人淋巴细胞产生淋巴因子激活的杀伤活性。
J Immunol. 1989 May 15;142(10):3452-61.
9
引用本文的文献
1
Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.抑制 N-糖基化加工可提高人自然杀伤细胞的抗体结合亲和力和效应功能。
Immunology. 2023 Oct;170(2):202-213. doi: 10.1111/imm.13662. Epub 2023 May 22.
2
Advanced T and Natural Killer Cell Therapy for Glioblastoma.用于胶质母细胞瘤的先进T细胞和自然杀伤细胞疗法。
J Korean Neurosurg Soc. 2023 Jul;66(4):356-381. doi: 10.3340/jkns.2022.0267. Epub 2023 Jan 2.
3
Next Generation Natural Killer Cells for Cancer Immunotherapy.下一代自然杀伤细胞用于癌症免疫治疗。
Front Immunol. 2022 Jun 2;13:886429. doi: 10.3389/fimmu.2022.886429. eCollection 2022.
4
There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment.从实践到理论，再从理论到实践：将过继细胞疗法应用于犬类癌症并改善人类治疗。
Vet Comp Oncol. 2021 Sep;19(3):420-427. doi: 10.1111/vco.12744. Epub 2021 Jul 18.
5
NK cells for cancer immunotherapy.自然杀伤细胞用于癌症免疫疗法。
Nat Rev Drug Discov. 2020 Mar;19(3):200-218. doi: 10.1038/s41573-019-0052-1. Epub 2020 Jan 6.
6
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.嵌合抗原受体修饰的自然杀伤细胞治疗胶质母细胞瘤：将固有效应细胞转化为癌症免疫治疗的精准工具。
Front Immunol. 2019 Nov 14;10:2683. doi: 10.3389/fimmu.2019.02683. eCollection 2019.
7
Delivering safer immunotherapies for cancer.为癌症提供更安全的免疫疗法。
Adv Drug Deliv Rev. 2017 May 15;114:79-101. doi: 10.1016/j.addr.2017.05.011. Epub 2017 May 22.
8
Chimeric antigen receptors: driving immunology towards synthetic biology.嵌合抗原受体：推动免疫学迈向合成生物学。
Curr Opin Immunol. 2016 Aug;41:68-76. doi: 10.1016/j.coi.2016.06.004. Epub 2016 Jun 30.
9
Regulation of mouse NK cell development and function by cytokines.细胞因子对小鼠自然杀伤细胞发育和功能的调控
Front Immunol. 2013 Dec 12;4:450. doi: 10.3389/fimmu.2013.00450.
10
IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.白细胞介素-2（IL-2）调控黑素瘤细胞中肿瘤抑制因子白细胞介素-24（IL-24）的表达。
Melanoma Res. 2012 Feb;22(1):19-29. doi: 10.1097/CMR.0b013e32834d2506.
本文引用的文献
1
Human T-cell growth factor: purification biochemical characterization, and interaction with a cellular receptor.人T细胞生长因子：纯化、生化特性及与细胞受体的相互作用。
Immunobiology. 1982 Mar;161(1-2):21-50. doi: 10.1016/S0171-2985(82)80018-1.
2
The purification and properties of human T cell growth factor.人T细胞生长因子的纯化及特性
J Immunol. 1982 Mar;128(3):1122-7.
3
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.在T细胞生长因子中培养的人淋巴细胞对新鲜的和培养的自体肿瘤的溶解作用。
Cancer Res. 1981 Nov;41(11 Pt 1):4420-5.
4
T cell growth factor receptors. Quantitation, specificity, and biological relevance.T细胞生长因子受体。定量、特异性及生物学相关性。
J Exp Med. 1981 Nov 1;154(5):1455-74. doi: 10.1084/jem.154.5.1455.
5
6
7
8
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor.一种似乎能识别人类T细胞生长因子受体的单克隆抗体；该受体的部分特性
Nature. 1982 Nov 18;300(5889):267-9. doi: 10.1038/300267a0.
9
Purification of human interleukin 1.人白细胞介素1的纯化
J Supramol Struct. 1980;13(4):457-66. doi: 10.1002/jss.400130405.
10
Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line.淋巴细胞调节分子的生化与生物学特性。V. 一株产生白细胞介素2的人白血病T细胞系的鉴定。
J Exp Med. 1980 Dec 1;152(6):1709-19. doi: 10.1084/jem.152.6.1709.
Zotero 插件